Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2553841 | 0.95 | HRH3 (0.44) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL2550326 | 0.93 | L3MBTL3 (0.46) | HRH3KCNH2KDM4EALDH1A1L3MBTL3 | |
| SCHEMBL3590543 | 0.91 | HRH3 (0.42) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL3768409 | 0.91 | POLB (0.56) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL65252 | 0.91 | POLB (0.52) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL861595 | 0.89 | HRH3 (0.41) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL3601428 | 0.89 | POLB (0.59) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL18619500 | 0.89 | POLB (0.59) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL13734715 | 0.86 | HRH3 (0.42) | HRH3KCNH2POLBHSD17B10KDM4E | |
| SCHEMBL3593939 | 0.85 | POLB (0.40) | HRH3KCNH2POLBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2875016-B1 | CARBAMATE/UREA DERIVATIVES | NOVARTIS AG (CH) | 2017-08-23 | — | — | EP | claimed |
| EP-2763978-B1 | CARBAMATE/ UREA DERIVATIVES CONTAINING PIPERIDIN AND PIPERAZIN RINGS AS H3 RECEPTOR INHIBITORS | NOVARTIS AG (CH) | 2017-02-01 | — | — | EP | claimed |
| WO-2012111995-A1 | OXIME DERIVATIVES AS GPR119 AGONISTS | LG LIFE SCIENCES LTD. (KR) | 2012-08-23 | — | — | WO | claimed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20170260143-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2017-09-14 | — | — | US | disclosed |
| US-9688640-B2 | Methods of treating cancer with a pyrazole derivative | ASTRAZENECA AB (SE) | 2017-06-27 | — | — | US | disclosed |
| US-20150299134-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2015-10-22 | — | — | US | disclosed |
| US-20140066455-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-03-06 | — | — | US | disclosed |
| US-8604022-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2013-12-10 | — | — | US | disclosed |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | MANI NEELAKANDHA S (US) | 2012-11-08 | — | — | US | disclosed |
| EP-1951699-B1 | PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-10 | — | — | EP | disclosed |
| EP-1948607-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | Janssen Pharmaceutica, N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20070197508-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-23 | — | — | US | disclosed |
| US-20070129351-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-06-07 | — | — | US | disclosed |
| WO-2007053386-A2 | PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053427-A2 | NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007035425-A2 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH3 3986/4885KCNH2 2560/4885POLB 3678/4885 |
| US-20070197508-A1 | NOVEL PROCESSES FOR THE PREPARATION OF PIPERAZINYL AND DIAZAPANYL BENZAMIDE DERIVATIVES | HRH2, HRH4, HRH1 | HRH3 4/4885KCNH2 72/4885POLB 3905/4885 |
| US-20070066821-A1 | CYCLOPROPYL AMINES AS MODULATORS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH2 | HRH3 1/4885KCNH2 866/4885POLB 4301/4885 |
| US-20140066455-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885KCNH2 3713/4885POLB 4299/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 1893/4885KCNH2 3739/4885POLB 3022/4885 |
| US-20070129351-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | HRH3 4/4885KCNH2 1974/4885POLB 4518/4885 |
| US-20120283433-A1 | NOVEL PROCESSES FOR THE PREPARATION OF CYCLOPROPYL-AMIDE DERIVATIVES | HRH4, HRH2, HRH1 | HRH3 4/4885KCNH2 1974/4885POLB 4518/4885 |
| US-20170260143-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885KCNH2 3713/4885POLB 4299/4885 |
| US-20150299134-A1 | NOVEL COMPOUNDS | SLC10A1, ABCB11, CYP11B1 | HRH3 3902/4885KCNH2 3713/4885POLB 4299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.